Literature DB >> 27174040

Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013).

B A Marker1, L G Barber1, C A Clifford2, S S Correa3, P L Thalhofer4, T A LaDue5, C M Mullin2, M L Sauerbrey6, C C Wood7.   

Abstract

Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis. Pamidronate has not been previously reported to cause tissue injury upon extravasation in dogs. The medical records of 11 client-owned dogs undergoing palliative treatment for primary bone tumors with known or suspected pamidronate extravasation reactions were reviewed. The majority of adverse events were low grade in nature, however in some cases, the reactions were severe and led to euthanasia in one instance. Time to complete resolution of lesions ranged from within several days to greater than one and a half months. Aside from the dog that was euthanized, no long-term sequelae of extravasation were identified. Treatments employed to address the reactions varied widely. Pamidronate extravasation reaction appears to be an uncommon, but potentially serious complication of intravenous administration.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  comparative oncology; oncology; small animal; small animal internal medicine; supportive care

Mesh:

Substances:

Year:  2016        PMID: 27174040     DOI: 10.1111/vco.12191

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  1 in total

1.  Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity.

Authors:  Katherine Ann Dawson; April Blong; Rebecca Walton
Journal:  Front Vet Sci       Date:  2022-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.